Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Effects of Silymarin on Treatment Naïve Patients with Chronic Hepatitis B Infection-A Randomized Controlled Trial

Okonkwo Uchenna C1*, Aluka Anthony2and Ezedinachi Emmanuel1
1Department of Internal Medicine, University of Calabar Teaching Hospital, Calabar, Nigeria
2Department of Family Medicine, University of Calabar Teaching Hospital, Calabar, Nigeria
Corresponding Author : Dr. Okonkwo UC
Department of Internal Medicine
University of Calabar Teaching Hospital
P.M.B. 1278, Calabar, Cross river state, Nigeria
Tel: +234 803 3251 240
Email: drucokonkwo@unical.edu.ng
Received July 07, 2014; Accepted September 23, 2014; Published September 30, 2014
Citation: Okonkwo Uchenna C, Aluka Anthony, Ezedinachi Emmanuel (2014) Effects of Silymarin on Treatment Naïve Patients with Chronic Hepatitis B Infection-A Randomized Controlled Trial. J Infect Dis Ther 2:168. doi:10.4172/2332-0877.1000168
Copyright: © 2014 Uchenna OC, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Related article at
DownloadPubmed DownloadScholar Google

Abstract

Background: Silymarin, an extract of milk thistle (silybum marianum) is widely used in the treatment of patients with chronic liver disease yet its beneficial effects remain controversial.

Aim: To determine the effect of silymarin on liver biochemistry and health related quality of life (HRQOL) in treatment naïve patients with chronic hepatitis B infection.

Methods: This was a double-blind randomized placebo-controlled trial conducted at the University of Calabar Teaching Hospital, Cross river state. Patients with chronic hepatitis B were randomized to receive silymarin or placebo for 4 weeks. Their liver function tests and HRQOL were assessed at baseline and post-treatment.

Results: Eighty-six persons were enrolled into the study. Seventy-nine completed the study. Silymarin use was associated (p<0.05) with improvement in serum alanine and aspartate aminotransferase and HRQOL from baseline but not with serum bilirubin and alkaline phosphatase.

Conclusion: Silymarin use among patients with chronic hepatitis B is associated with improvement in liver function tests especially markers of liver inflammation and HRQOL.

Keywords

Top